- Home
- ALHC vs VKTX Comparison
ALHC vs VKTX Comparison
Compare ALHC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALHC | VKTX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALHC | VKTX |
|---|---|---|
| Price | $19.15 | $35.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $20.23 | ★ $87.07 |
| AVG Volume (30 Days) | ★ 2.8M | 2.4M |
| Earning Date | 10-30-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,637,156,000.00 | N/A |
| Revenue This Year | $48.66 | N/A |
| Revenue Next Year | $31.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.39 | N/A |
| 52 Week Low | $10.55 | $18.92 |
| 52 Week High | $21.06 | $43.55 |
Technical Indicators
Market Signals| Indicator | ALHC | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.65 | 46.26 |
| Support Level | $18.23 | $36.00 |
| Resistance Level | $20.35 | $37.83 |
| Average True Range (ATR) | 0.67 | 1.49 |
| MACD | -0.20 | -0.04 |
| Stochastic Oscillator | 36.77 | 30.91 |
Price Performance
Historical ComparisonAbout ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.